Finance

Lists
CTMX:NASDAQ
CytomX Therapeutics Inc
$3.71
+0.82%
(+0.030) 1D
$3.71
-0.03% (-0.00100)
After hours
Closed: Sep 4, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTMX...
Open
$3.64
High
$3.72
Low
$3.53
Mkt. cap
808.41M
Avg. vol.
2.80M
Volume
2.30M
52-wk high
$8.20
52-wk low
$1.90
EPS
-$0.46
Beta
2.15
Shares outstanding
217.90M
No. of employees
69
Open
$3.64
High
$3.72
Low
$3.53
Mkt. cap
808.41M
Avg. vol.
2.80M
Volume
2.30M
52-wk high
$8.20
52-wk low
$1.90
EPS
-$0.46
Beta
2.15
Shares outstanding
217.90M
No. of employees
69
News stories
From web sources and news partners
About CytomX Therapeutics Inc
CEO-
Employees69
Founded2008
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytomx.com
Analyst ratings
Based on 4 analysts giving stock ratings to CTMX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CTMX in the last 3 months.
Highest
Current $3.71
$16.00 (+331.27%)
Average
$13.25 (+257.14%)
Lowest
$11.00 (+196.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Maintained
$11.00
+196.5%
08/17/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$12.00
+223.5%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
$16.00
+331.3%
08/07/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$14.00
+277.4%
08/07/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$11.00
+196.5%
06/04/2026
Kalpit Patel
Wolfe Research
Buy
Initiated
$6.00
+61.7%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$12.00
+223.5%
05/13/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Maintained
$11.00
+196.5%
05/11/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$12.00
+223.5%
03/20/2026
Roger Song
Jefferies
Buy
Reiterated
$16.00
+331.3%
03/18/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.09 / -$0.11
+14.64%beat
Revenue / Est. (USD)
1.42M / 12.34M
-88.51%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.96M
663.00K
10.26M
1.42M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
15.30M
19.54M
19.24M
17.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.43M
6.26M
10.69M
7.60M
Operating expense
21.73M
25.80M
29.93M
25.20M
Total operating expenses
21.73M
25.80M
29.93M
25.20M
Operating income
-15.77M
-25.13M
-19.67M
-23.78M
Other non operating income
-
-
-
-
EBT including unusual items
-14.17M
-26.46M
-18.19M
-20.61M
EBT excluding unusual items
-14.17M
-23.66M
-18.19M
-20.61M
Income tax expense
58.00K
54.00K
59.00K
60.00K
Effective tax rate
-0.41%
-0.20%
-0.32%
-0.29%
Other operating expenses
-
-
-
-
Net income
-14.23M
-26.51M
-18.25M
-20.67M
Net profit margin
-238.62%
-3,998.49%
-177.89%
-1,457.40%
Earnings per share
-0.09
-0.22
-0.10
-0.09
Interest and investment income
1.59M
1.48M
1.49M
3.16M
Interest expense
-
-
-
-
Net interest expenses
1.59M
1.48M
1.49M
3.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.63M
-24.62M
-19.42M
-23.73M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps